A new treatment option is now available on the NHS for cervical cancer that has come back or spread to other parts of the body, following our final draft guidance published today.

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...

Teplizumab is the disease-modifying therapy for type 1 diabetes and England is the first country in Europe to recommend it's use through a health technology appraisal.

Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA1167 18 June 2026 18 June 2026 ...

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...

This guideline has been updated and replaced by NICE guideline NG258 ...

Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] ...

Browse guidance by topic Cancer Biliary tract cancers Bladder cancer Blood and bone marrow cancers Brain cancers Breast cancer Cervical cancer Colorectal cancer Complications of cancer Endometrial ...

NICE’s healthtech guidance provided me with the perfect catalyst for change.

Critical assessment of evidence to help you make decisions. Advice, rather than formal NICE guidance.

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...